NO20044945L - Tcelle reseptor CDR3 sekvenser og fremgangsmater for deteksjon - Google Patents

Tcelle reseptor CDR3 sekvenser og fremgangsmater for deteksjon

Info

Publication number: NO20044945L
Authority: NO; Norway
Prior art keywords: methods; detection; cell receptor; cdr3 sequences; receptor cdr3
Prior art date: 2002-06-05

Application number

NO20044945A

Other languages

English (en)

Norwegian (no)

Inventor

Jingwu Z Zhang

Original Assignee

Opexa Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-05

Filing date

2004-11-12

Publication date

2004-12-28

2004-11-12 Application filed by Opexa Pharmaceuticals Inc filed Critical Opexa Pharmaceuticals Inc

2004-12-28 Publication of NO20044945L publication Critical patent/NO20044945L/no

Links

108091008874 T cell receptors Proteins 0.000 title abstract 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
101100112922 Candida albicans CDR3 gene Proteins 0.000 title 1
238000001514 detection method Methods 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 abstract 3
208000023275 Autoimmune disease Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
238000012544 monitoring process Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pathology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)

NO20044945A 2002-06-05 2004-11-12 Tcelle reseptor CDR3 sekvenser og fremgangsmater for deteksjon NO20044945L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38628702P	2002-06-05	2002-06-05
PCT/US2003/017873 WO2003104407A2 (en)	2002-06-05	2003-06-05	T cell receptor cdr3 sequences and methods for detection

Publications (1)

Publication Number	Publication Date
NO20044945L true NO20044945L (no)	2004-12-28

Family

ID=29736145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044945A NO20044945L (no)	2002-06-05	2004-11-12	Tcelle reseptor CDR3 sekvenser og fremgangsmater for deteksjon

Country Status (16)

Country	Link
EP (1)	EP1530483B1 (de)
JP (3)	JP2005528910A (de)
CN (1)	CN1674931A (de)
AT (1)	ATE453727T1 (de)
AU (1)	AU2003237437B2 (de)
BR (1)	BR0311578A (de)
CA (1)	CA2485874A1 (de)
DE (1)	DE60330780D1 (de)
IL (2)	IL165194A (de)
MX (1)	MXPA04011646A (de)
NO (1)	NO20044945L (de)
NZ (1)	NZ537403A (de)
PL (1)	PL213315B1 (de)
RU (1)	RU2004139045A (de)
WO (1)	WO2003104407A2 (de)
ZA (1)	ZA200409792B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE536867T1 (de)	2006-03-16	2011-12-15	Tris Pharma Inc	Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
CA2880456A1 (en)	2012-08-15	2014-02-20	Tris Pharma, Inc.	Methylphenidate extended release chewable tablet
US11590228B1 (en)	2015-09-08	2023-02-28	Tris Pharma, Inc	Extended release amphetamine compositions
CN108070644B (zh) *	2016-11-08	2021-06-29	国家卫生计生委科学技术研究所	一种妊娠高血压的诊断系统
US11858994B2 (en)	2017-03-15	2024-01-02	Repertoire Genesis Incorporation	Biomarkers for cancer immunotherapy
US12458592B1 (en)	2017-09-24	2025-11-04	Tris Pharma, Inc.	Extended release amphetamine tablets
US11590081B1 (en)	2017-09-24	2023-02-28	Tris Pharma, Inc	Extended release amphetamine tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL97709A (en) *	1990-03-30	2005-05-17	Brigham & Womens Hospital	Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
AU774952B2 (en) *	1999-02-23	2004-07-15	Baylor College Of Medicine	T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection

2003
- 2003-06-05 PL PL374723A patent/PL213315B1/pl unknown
- 2003-06-05 BR BRPI0311578-0A patent/BR0311578A/pt not_active IP Right Cessation
- 2003-06-05 AU AU2003237437A patent/AU2003237437B2/en not_active Ceased
- 2003-06-05 AT AT03736888T patent/ATE453727T1/de not_active IP Right Cessation
- 2003-06-05 EP EP03736888A patent/EP1530483B1/de not_active Expired - Lifetime
- 2003-06-05 RU RU2004139045/13A patent/RU2004139045A/ru not_active Application Discontinuation
- 2003-06-05 NZ NZ537403A patent/NZ537403A/en not_active IP Right Cessation
- 2003-06-05 JP JP2004511467A patent/JP2005528910A/ja not_active Withdrawn
- 2003-06-05 DE DE60330780T patent/DE60330780D1/de not_active Expired - Lifetime
- 2003-06-05 CA CA002485874A patent/CA2485874A1/en not_active Abandoned
- 2003-06-05 CN CNA038186314A patent/CN1674931A/zh active Pending
- 2003-06-05 MX MXPA04011646A patent/MXPA04011646A/es not_active Application Discontinuation
- 2003-06-05 WO PCT/US2003/017873 patent/WO2003104407A2/en not_active Ceased
2004
- 2004-11-12 NO NO20044945A patent/NO20044945L/no not_active Application Discontinuation
- 2004-11-14 IL IL165194A patent/IL165194A/en not_active IP Right Cessation
- 2004-12-02 ZA ZA200409792A patent/ZA200409792B/en unknown
2010
- 2010-04-01 JP JP2010085593A patent/JP2010207226A/ja not_active Withdrawn
- 2010-06-27 IL IL206650A patent/IL206650A/en not_active IP Right Cessation
2013
- 2013-03-05 JP JP2013042552A patent/JP2013126420A/ja active Pending

Also Published As

Publication number	Publication date
IL165194A (en)	2010-11-30
CN1674931A (zh)	2005-09-28
ATE453727T1 (de)	2010-01-15
BR0311578A (pt)	2007-04-27
CA2485874A1 (en)	2003-12-18
IL206650A0 (en)	2011-07-31
ZA200409792B (en)	2006-07-26
EP1530483A4 (de)	2006-05-17
IL206650A (en)	2016-10-31
DE60330780D1 (de)	2010-02-11
WO2003104407A2 (en)	2003-12-18
JP2005528910A (ja)	2005-09-29
MXPA04011646A (es)	2005-03-07
EP1530483B1 (de)	2009-12-30
RU2004139045A (ru)	2005-09-10
JP2010207226A (ja)	2010-09-24
NZ537403A (en)	2009-10-30
EP1530483A2 (de)	2005-05-18
JP2013126420A (ja)	2013-06-27
PL374723A1 (en)	2005-10-31
WO2003104407A3 (en)	2005-03-24
AU2003237437A1 (en)	2003-12-22
PL213315B1 (pl)	2013-02-28
IL165194A0 (en)	2005-12-18
AU2003237437B2 (en)	2010-11-25

Legal Events

Date	Code	Title	Description
2009-02-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
Graham et al.	2020	Pathway paradigms revealed from the genetics of inflammatory bowel disease
IL206650A0 (en)	2011-07-31	T cell receptor cdr3 peptide for treating an autoimmune disease
Villani et al.	2018	Systems immunology: learning the rules of the immune system
TW200616657A (en)	2006-06-01	Therapeutic peptides and method
DK1187591T3 (da)	2010-06-28	IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
US20210033608A1 (en)	2021-02-04	Methods and Systems for Identification of Human Leukocyte Antigen Peptide Presentation and Applications Thereof
ATE293169T1 (de)	2005-04-15	Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ATE417103T1 (de)	2008-12-15	Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklus
DE69831500T2 (de)	2006-06-14	Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
Townsend et al.	2024	Innovations and trends in antibody repertoire analysis
ATE534669T1 (de)	2011-12-15	Verfahren zum erhalten von anti-idiotyp antikörpern
ATE316577T1 (de)	2006-02-15	Das goodpasture-antigen bindende protein
EP2192407A3 (de)	2011-04-27	Verfahren zum Nachweis von Zellimmunität und ihre Anwendung auf Arzneimittel
AU2002341090A1 (en)	2003-03-24	Use of a protein of the crmp family for treating diseases related to the immune system
DK1523548T3 (da)	2010-05-10	Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
DE60127663D1 (de)	2007-05-16	Cng3b: neuartiger, zyklischer nukleotid-abhängiger kationenkanal
TR200100175T2 (tr)	2001-09-21	Otoimmün hastalıkların immünoterapisinde kullanılmak üzere yeni peptitler.
HUP0301111A2 (hu)	2003-08-28	Potenciálisan immundomináns acetilkolin-receptor oligopeptideket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1796707A4 (de)	2009-09-09	Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
AU2003302440A8 (en)	2004-06-18	Nucleic acid probes and method for detecting a target nucleic acid sequence comprise two or more cis- located nucleic acid regions
Berthet et al.	2017	MgI2‐chemoselective cleavage for removal of amino acid protecting groups: A fresh vision for peptide synthesis
DK1512004T3 (da)	2006-06-06	Fremgangsmåde til kortlægning og eliminering af T-celleepitoper
DK1569961T3 (da)	2010-04-12	Splice variant af det menneskelige hypofysevæksthormon
Mbulaiteye et al.	2025	57th Session of the International Seminars on Planetary Emergencies 9-14 August 2025
Schwämmle et al.	0	Wednesday, June 29, 08: 30, Room: AM7 Chaired by: Stanisław Cebrat